DEXAMETHASONE - dexamethas one injection, solution Vedco, Inc.

DEXAMETHASONE INJECTION 2 mg/mL

Solution for intravenous or intramuscular injection

Veterinary

CAUTION

Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

DEXAMETHASONE INJECTION 2 mg/mL is a synthetic analogue of prednisolone, having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects. Modification of the basic corticoid structure as achieved in DEXAMETHASONE INJECTION 2 mg/mL offers enhanced anti-inflammatory effect compared to older corticosteroids. The dosage of DEXAMETHASONE INJECTION 2 mg/mL required is markedly lower than that of prednisone and prednisolone.

DEXAMETHASONE INJECTION 2 mg/mL is not species-specific; however, the veterinarian should read the sections on **INDICATIONS**, **DOSAGE**, **SIDE EFFECTS**, **CONTRAINDICATIONS**, **PRECAUTIONS**, and **WARNINGS** before this drug is used.

DEXAMETHASONE INJECTION 2 mg/mL is intended for *intravenous or intramuscular* administration. Each mL contains 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.

EXPERIMENTAL STUDIES

Experimental animal studies on dexamethasone have revealed it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately twenty times the anti-inflammatory activity of prednisolone and seventy to eighty times that of hydrocortisone. Thymus involution studies show dexamethasone possesses twenty-five times the activity of prednisolone. In reference to mineralocorticoid activity, dexamethasone does not cause significant sodium or water retention. Metabolic balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.

INDICATIONS

DEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.

As supportive therapy, DEXAMETHASONE INJECTION 2 mg/mL may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. DEXAMETHASONE INJECTION 2 mg/mL may be used intravenously as supportive therapy when an immediate hormonal response is required.

Bovine Ketosis

DEXAMETHASONE INJECTION 2 mg/mL is offered for the treatment of primary ketosis. The gluconeogenic effects of DEXAMETHASONE INJECTION 2 mg/mL, when administered intramuscularly, are generally noted within the first 6 to 12 hours. When DEXAMETHASONE

INJECTION 2 mg/mL is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. Acetone bodies are reduced to normal concentrations usually within 24 hours. The physical attitude of animals treated with DEXAMETHASONE INJECTION 2 mg/mL brightens and appetite improves, usually within 12 hours. Milk production, which is suppressed as a compensatory reaction in this condition, begins to increase. In some instances, it may even surpass previous peaks. The recovery process usually takes from 3 to 7 days.

Supportive Therapy

DEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in mastits, metritis, traumatic gastritis, and pyelonephritis, while appropriate primary therapy is administered. In these cases, the corticosteroid combats accompanying stress and enhances the feeling of general well-being. DEXAMETHASONE INJECTION 2 mg/mL may also be used as supportive therapy in inflammatory conditions, such as arthritic conditions, snake bite, acute mastitis, shipping fever, pneumonia, laminitis, and retained placenta.

Equine

DEXAMETHASONE INJECTION 2 mg/mL is indicated for the treatment of acute musculoskeletal inflammations, such as bursitis, carpitis, osselets, tendonitis, myositis, and sprains. If boney changes exist in any of the conditions, joints, or accessory structures, responses to DEXAMETHASONE INJECTION 2 mg/mL cannot be expected. In addition, DEXAMETHASONE INJECTION 2 mg/mL may be used as supportive therapy in fatigue, heat exhaustion, influenza, laminitis, and retained placenta provided that the primary cause is determined and corrected.

ADMINISTRATION AND DOSAGE

Therapy with DEXAMETHASONE INJECTION 2 mg/mL, as with any other potent corticosteroid, should be individualized according to the severity of the condition being treated, anticipated duration of steroid therapy, and teh animal's threshold or tolerance for steroid excess.

Treatment may be changed over to DEXAMETHASONE INJECTION2 mg/mL from any other glucocorticoid with proper reduction or adjustment of dosage.

Bovine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEXAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

CONTRAINDICATIONS

Except for emergency therapy, do not use in animals with chronic nephritis and hypercorticalism (Cushing's syndrome). Existence of congestive heart failure, diabetes, and osteoporosis are relative contraindications. Do not use in viral infections during the viremic stage.

PRECAUTIONS

Animals receiving DEXAMETHASONE INJECTION 2 mg/mL should be under close observation. Because of the anti-inflammatory action of corticosteroids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss, and weight gain.

DEXAMETHASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.

Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapid acting corticosteroid should be considered in unusually stressful situations.

WARNINGS

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

SIDE EFFECTS

Side effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats.

Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Corticosteroids reportedly cause laminitis in horses.

HOW SUPPLIED

DEXAMETHASONE INJECTION 2 mg/mL, 100 mL multiple dose vial.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).

Protect from freezing.

Each mL contains: 2 mg dexamethasone; 500 mg polyethylene glycol 400; 9 mg benzyl alcohol, 1.8 mg methylparaben, and 0.2 mg propylparaben as preservatives; 4.75% alcohol; HCl to adjust pH to approximately 4.9; water for injection qs.

TAKE TIME OBSERVE LABEL DIRECTIONS

Veterinary FOR ANIMAL USE ONLY

For Intravenous or Intra-muscular Injection Usual Dose

Bovine-5 to 20 mg Equine-2.5 to 5 mg

NDC 50989-437-12

VETERINARY

ANADA 200-324, Approved by FDA

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



For Intravenous or Intramuscular Injection

Usual Dose:

Bovine-5 to 20 mg Equine-2.5 to 5 mg

Warning: A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C excursions permitted between 1 and 30°C (between 59°F and 86°F).

Protect from freezing READ ACCOMPANYING DIRECTIONS CAREFULLY

LOT NO .:

EXP. DATE:



Each mL contains: 2 mg dexamethasone; 500 mg polyethylene glycol 400; 9 mg benzyl alcohol, 1.8 mg methylparaben, and 0.2 mg propylparaben as preservatives; 4.75% alcohol; HCl to adjust pH to approximately 4.9; water for injection qs.



Veterinary FOR ANIMAL USE ONLY

VINV-DEX2-100M

Distributed By Manufactured by VEDCO, INC. St. Joseph, MO 64507 Lenexa, KS 66215, USA Sparhawk Laboratories, Inc.

Rev. 11-12

D-2953-04

Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs phocomelis, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

to be processed for vew.

SIDE EFFECTS
Side effects, such as SAP and SGPT enzyme
elevations, weight losts, annexis, polytipsia, and
polyuris have occurred following the use of synthetic
corticosteroids in dogs. Womitting and dismitting and
similar decorticosteroids in dogs. Womitting and
similar decorticosteroids in dogs and

Cushing's syndrome in dogs has been reporter association with prolonged or repeated ste

eroids reportedly cause laminitis in horses

HOW SUPPLIED
DEXAMETHASONE INJECTION 2 mg/mL, 100 mL

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Protect from freezing

D-2953-04

Manufactured by Sparhawk Laboratories, Inc. Lenexa, KS 66215, USA

ANADA#: 200-324, Approved by FDA

Each mL contains: 2 mg dexameth-asone; 500 mg polyethylene glycol 400; 9 mg benzyl alcohol, 1.8 mg methyl-paraben, and 0.2 mg propylparaben as preservatives; 4.75% alcohol; HCI to adjust pH to approximately 4.9; water for injection qs.



Veterinary FOR ANIMAL USE ONLY

Distributed By Manufactured by VEDCO, INC. Sparhawk Laboratories, Inc. St. Joseph, MO 64507 Lenexa, KS 66215, USA VINV-DEX2-100M

Rev. 11-12

DEXAMETHASONE INJECTION 2 mg/mL

Veterinary

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

order of a locenses vesor-DESCRIPTION
DEXAMETHASONE INJECTION 2 mg/mL is a synthetic analogue of prechisolone, having similar but more potest arti-inflammatory therapeutic action and diversified homeonal and metabolic effects. Modification of the basic corticold structure as achieved in DEXAMETHASONE BURGETION 2 mg/m1, offers enhanced anti-inflammatory effect compared to offers enhanced anti-inflammatory effect comp older corticosteroids. The dosage DEXAMETHASONE INJECTION 2 mg/mL req markedly lower than that of prednison

DEXAMETHASONE INJECTION 2 mg/mL i species-specific however, the veterinarian should read the sections on INDICATIONS, DOSAGE, SIDE EFFECTS, CONTRAINDICATIONS, PRECAUTIONS, and WARNINGS before this drops is seen.

EFFELTS, CONTINUATIONAL TIONS, PRECULTIONS, and WARNINGS before this drug is used.

DEXAMETHASONE INJECTION 2 mg/ml, is intended for intravenous or intramuscular administration. Each III, contains 2 mg dexamethasone, 500 mg polythyfine glybol 400, 9 mg bennyl alcohol, 1.8 mg methylgaraben and 0.2 mg propylgaraben as preservatine, 4.75% salcohol, 410 to adjust pH to approximately 4.9, water for injection q.s.

approximately 4.9, water for injection q.s. EVFRIMENTAL STUDIES Experimental arimal studies on dexamethasone have revealed it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately twenty times the anti-inflammatory activity of predisciolene and sevenely to eligibly times that of hydrocortisone. Thymus involution studies show dexamethasone possesses twenty-five times the mineralocorticoid activity, dexamethasone does not the mineralocorticoid activity, dexamethasone does not

INDICATIONS
DEXAMETHASONE INJECTION 2 mg/mL is indic

DEXAMETHASONE INJECTION 2 mg/ml, is indicated for the treatment of primary bovine storiss and as an anti-inflammatory agent in the bovine and equine.

As supportive therapy, DEXAMETHASONE INJECTION 2 mg/ml, may be used in the management of various freumatic, allerge, the management of a various freumatic, allerge, the management of a various freumatic, allerge, the management of the properties of the prop

Bovine Ketosis
DEXAMETHASONE INJECTION 2 mg/ml. is offered
for the treatment of primary ketosis. The
gluconeogenic effects of DEXAMETHASONE
NUECTION 2 mg/ml. when administered
intramsocularly, an generally noded within the first of
to 2 hours. When DEXAMETHASONE BUECTION 2

mg/mL is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels may be represented by the properties of the properties of

recovery process usually takes from 3 to 2 args.
Spaportive Theres (TNJECTION 2 mg/mL may be
used as supportive therapy in mastitis, metritis,
traumatic gastritis, and pyelonephritis, traumatic gastritis, and pyelonephritis, traumatic gastritis, and pyelonephritis, while
appropriate primary therapy is administered. In these
cases, the corticosteroid combats accompanying
stress and enhances the feeling of general well-being.
DEXAMETHASONE INJECTION 2 mg/mL may also
be used as supportive therapy in inflammatics,
acute mastitis, shipping fever, pneumonia, laminitis,
and retained placents.

4

Equine
DEAMNETHASONE INJECTION 2 mg/lml. is indicated for the treatment of acute musculoskeletal inflammations, such as burdist, capitis, seelests, tendonitis, myeatis, and sprains. If boney changes exist in any of the conditions, joints, or accessory structures, responses to DEXAMETHASONE INJECTION 2 mg/lml. cannot be septed. In addition. DEXAMETHASONE INJECTION 2 mg/lml. may be used to be accessed to the conditions, joint and the conditions of the conditio

correctors.

ADMINISTRATION AND DOSAGE
Therapy with DEXAMETHASONE INJECTION 2
mg/ml, as with any other potent corticosteroid,
should be individualized according to the severity of
the condition being treated, articipated duration of
steroid therapy, and the animal's threshold or
tolerance for steroid excess.

Treatment may be changed over to DEXAMETHASONE INJECTION 2 mg/ml, from any other glucocorticoid with proper reduction or DEXAMETHASUNE notice of the property of the property of dosage.

Bovine - DEXAMETHASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

Equine - DEXAMETHASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.

Dexamethasone Powder may be administered or the parenteral dose repeated as needed.

parenterial dose repeated as necodo.

CONTRANDICATIONS

Except for emergency therapy, do not use in animals with chronic nephritis and hypercorticalism (Cushing's syndrome). Existence of congestive heart failure, diabetes, and osteoprorosis are relative contraindications. Do not use in viral inflections during the virente stage.

the viennic stage.

PRECAUTIONS
Animals receiving DEXAMETHASONE INJECTION 2
Animals receiving DEXAMETHASONE INJECTION 2.

Injimit, should be under close observation. Because of the anti-inflammatory action of conticosteroids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may 6

result in sodium retention, fluid retention, loss, and weight gain.

loss, and weight gain.

DEXAMETHASONE INJECTION 2 mg/ml. may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.

Doses greater than those recommended in horses may produce a transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.

some nonse. The tending vasually acutes in 24 noun-l. Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdraws from systemic corticosteroid restaments, therapy with a rapid acting corticosteroid should be considered in unusually stressful situations.

DEXAMETHASONE

dexamethasone injection, solution

Product Information PRESCRIPTION ANIMAL DRUG NDC:50989-Product Type Item Code (Source) LABEL 437 INTRAMUSCULAR, **Route of Administration DEA Schedule** INTRAVENOUS

Active Ingredient/Active Moiety						
Ingredient Name	Basis of Strength	Strength				

DEXAMETHASONE (DEXAMETHASONE)		DEXAMETHASONE		2 mg in 1 mL			
Packaging							
#	Item Code	Package Description	Marke	eting Start Date	Marketing End Date		
1	NDC:50989-437-12	100 mL in 1 VIAL, MULTI-DOSE					
Marketing Information							
N.	larketing Category	Application Number or Monograph	Citation	Marketing Start Date	Marketing End Date		
AN	NADA	ANADA200324		02/21/2006			

Labeler - Vedco, Inc. (021634266)

Revised: 12/2012 Vedco, Inc.